| Literature DB >> 26233724 |
Abstract
The major abnormality in both type 1 and type 2 diabetes is insulin deficiency. The methods of replacing insulin have improved throughout the decades, but hypoglycemia is still the limiting factor for many individuals with diabetes, and it prevents them from achieving ideal glycemic targets. New insulin and newer delivery systems are being developed that can improve some of the limitations of current insulins or make the delivery of insulins more acceptable for some patients. Extending the duration of action of basal insulins and shortening the peak of fast-acting insulins may have advantages for individuals with diabetes. Different delivery systems may make insulin more acceptable to patients and may have other advantages, which may aid in attaining better glycemic control.Entities:
Keywords: basal insulin; degludec; diabetes; diabète; glargine U300; insuline basale; pegylated lispro; pégylé lispro
Mesh:
Substances:
Year: 2015 PMID: 26233724 DOI: 10.1016/j.jcjd.2015.04.006
Source DB: PubMed Journal: Can J Diabetes ISSN: 1499-2671 Impact factor: 4.190